M.V. Bluthgen

747 total citations
18 papers, 424 citations indexed

About

M.V. Bluthgen is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Neurology. According to data from OpenAlex, M.V. Bluthgen has authored 18 papers receiving a total of 424 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Pulmonary and Respiratory Medicine, 9 papers in Oncology and 4 papers in Neurology. Recurrent topics in M.V. Bluthgen's work include Lung Cancer Treatments and Mutations (7 papers), Cancer Immunotherapy and Biomarkers (6 papers) and Myasthenia Gravis and Thymoma (4 papers). M.V. Bluthgen is often cited by papers focused on Lung Cancer Treatments and Mutations (7 papers), Cancer Immunotherapy and Biomarkers (6 papers) and Myasthenia Gravis and Thymoma (4 papers). M.V. Bluthgen collaborates with scholars based in France, Argentina and Germany. M.V. Bluthgen's co-authors include Benjamin Besse, Jordi Remón, David Planchard, Jean‐Charles Soria, Ludovic Lacroix, Caroline Caramella, Laura Faivre, Jean‐Pierre Pignon, Anas Gazzah and Édouard Auclin and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and European Journal of Cancer.

In The Last Decade

M.V. Bluthgen

17 papers receiving 420 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
M.V. Bluthgen France 8 243 238 180 98 52 18 424
Israel Cañadas Spain 9 289 1.2× 211 0.9× 109 0.6× 183 1.9× 27 0.5× 11 487
Greg Jones United States 10 189 0.8× 237 1.0× 266 1.5× 153 1.6× 11 0.2× 22 473
Andri Papakonstantinou Sweden 11 237 1.0× 198 0.8× 151 0.8× 87 0.9× 10 0.2× 33 419
Monica Barbolini Italy 9 254 1.0× 96 0.4× 117 0.7× 127 1.3× 19 0.4× 26 399
Barbara Szostakiewicz Poland 7 245 1.0× 233 1.0× 90 0.5× 151 1.5× 11 0.2× 20 437
Andrea E. Doak United States 6 200 0.8× 253 1.1× 128 0.7× 161 1.6× 7 0.1× 7 350
Maria Antonietta Satolli Italy 14 293 1.2× 100 0.4× 85 0.5× 116 1.2× 25 0.5× 29 440
María San Román Spain 11 182 0.7× 98 0.4× 49 0.3× 130 1.3× 12 0.2× 16 343
Levi Sokol United States 6 254 1.0× 91 0.4× 118 0.7× 97 1.0× 19 0.4× 8 438
Camille Evrard France 9 252 1.0× 43 0.2× 140 0.8× 79 0.8× 63 1.2× 19 393

Countries citing papers authored by M.V. Bluthgen

Since Specialization
Citations

This map shows the geographic impact of M.V. Bluthgen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M.V. Bluthgen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M.V. Bluthgen more than expected).

Fields of papers citing papers by M.V. Bluthgen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M.V. Bluthgen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M.V. Bluthgen. The network helps show where M.V. Bluthgen may publish in the future.

Co-authorship network of co-authors of M.V. Bluthgen

This figure shows the co-authorship network connecting the top 25 collaborators of M.V. Bluthgen. A scholar is included among the top collaborators of M.V. Bluthgen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M.V. Bluthgen. M.V. Bluthgen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Bluthgen, M.V., Neus Basté, & Gonzalo Recondo. (2020). Immunotherapy Combinations for the Treatment of Patients with Solid Tumors. Future Oncology. 16(23). 1715–1736. 7 indexed citations
2.
Noël, Nicolas, A. Hot, David Saadoun, et al.. (2020). Systemic lupus erythematosus associated with thymoma: A fifteen-year observational study in France. Autoimmunity Reviews. 19(3). 102464–102464. 6 indexed citations
3.
4.
Mezquita, Laura, Caroline Rossoni, Édouard Auclin, et al.. (2019). MA25.03 Tumor-Infiltrating Lymphocytes (TIL) and Outcomes with Immunotherapy (ICI) or Chemotherapy in Advanced NSCLC (aNSCLC) Patients. Journal of Thoracic Oncology. 14(10). S351–S352. 2 indexed citations
5.
Rouquette, Isabelle, Julia Gilhodes, M.V. Bluthgen, et al.. (2019). Immune biomarkers in thymic epithelial tumors: expression patterns, prognostic value and comparison of diagnostic tests for PD-L1. Biomarker Research. 7(1). 28–28. 32 indexed citations
6.
Remón, Jordi, Caroline Caramella, Cécile Jovelet, et al.. (2017). Osimertinib benefit inEGFR-mutant NSCLC patients withT790M-mutation detected by circulating tumour DNA. Annals of Oncology. 28(4). 784–790. 133 indexed citations
7.
Lindsay, Colin R., Vincent Faugeroux, Stefan Michiels, et al.. (2017). A prospective examination of circulating tumor cell profiles in non-small-cell lung cancer molecular subgroups. Annals of Oncology. 28(7). 1523–1531. 73 indexed citations
8.
Mezquita, Laura, Mélinda Charrier, Laura Faivre, et al.. (2017). Prognostic value of HLA-A2 status in advanced non-small cell lung cancer patients. Lung Cancer. 112. 10–15. 4 indexed citations
9.
Bluthgen, M.V., Laura Faivre, Silvia Rosellini, et al.. (2017). Prognostic value of histogram analysis in advanced non-small cell lung cancer: a radiomic study. Oncotarget. 9(2). 1906–1914. 11 indexed citations
10.
Bluthgen, M.V., Laura Faivre, Jean‐Pierre Pignon, et al.. (2017). LKB1/STK11 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value. Lung Cancer. 112. 62–68. 88 indexed citations
11.
Lahmar, J., Laura Mezquita, Serge Koscielny, et al.. (2016). Immune checkpoint inhibitors (IC) induce paradoxical progression in a subset of non-small cell lung cancer (NSCLC). Annals of Oncology. 27. vi423–vi423. 12 indexed citations
12.
13.
Remón, Jordi, et al.. (2016). Thymic malignancies: Moving forward with new systemic treatments. Cancer Treatment Reviews. 46. 27–34. 3 indexed citations
14.
Gautschi, Oliver, M.V. Bluthgen, Egbert F. Smit, et al.. (2015). Targeted Therapy for Braf-Mutant Lung Cancer: Results from the European Euraf Cohort Study. Annals of Oncology. 26. i57–i57. 2 indexed citations
15.
Caramella, Caroline, M.V. Bluthgen, Charles Leduc, et al.. (2015). 3133 Prognostic value of texture analysis and correlation with molecular profile in EGFR mutated/ALK rearranged advanced non-small cell lung cancer (NSCLC). European Journal of Cancer. 51. S647–S648. 7 indexed citations
16.
Bluthgen, M.V., Caroline Caramella, Laurence Faivre, et al.. (2015). 3127 Prognostic value of texture analysis in advanced non-small cell lung cancer (NSCLC). European Journal of Cancer. 51. S645–S646. 4 indexed citations
17.
Bluthgen, M.V. & Benjamin Besse. (2015). Second-line combination therapies in nonsmall cell lung cancer without known driver mutations. European Respiratory Review. 24(138). 582–593. 17 indexed citations
18.
Rigas, James R., et al.. (2004). Thrombosis complicating advanced non-small cell lung cancer (NSCLC) treatment. Journal of Clinical Oncology. 22(14_suppl). 8082–8082. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Israel Cañadas Breakdown of academic impact, for papers by Greg Jones Breakdown of academic impact, for papers by Andri Papakonstantinou Breakdown of academic impact, for papers by Monica Barbolini Breakdown of academic impact, for papers by Barbara Szostakiewicz Breakdown of academic impact, for papers by Andrea E. Doak Breakdown of academic impact, for papers by Maria Antonietta Satolli Breakdown of academic impact, for papers by María San Román Breakdown of academic impact, for papers by Levi Sokol Breakdown of academic impact, for papers by Camille Evrard
Rankless by CCL
2026